Modality
Multispecific
MOA
TROP-2 ADC
Target
VEGF
Pathway
PD-1/PD-L1
HCCEoEEwing Sarcoma
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ Feb 2030
Phase 1Current
NCT06448755
588 pts·EoE
2018-08→2030-02·Recruiting
588 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-013.8y awayInterim· EoE
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Recruit…
Catalysts
Interim
2030-02-01 · 3.8y away
EoE
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06448755 | Phase 1 | EoE | Recruiting | 588 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF |